VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced the formation of its therapeutics advisory team and the appointment of a new Vice-President, Preclinical Research and Development.
